Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 Profit Margin

As of the most recent data (June 2026), CYCCP shows a profit margin of -213.82%. That compares with 8726.37% in the prior-year period — down 102.5% year over year. That is below the Healthcare sector average of 13.89%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYCCP's profit margin is now -213.82% (was 8726.37%) — a 102.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 is outperforming or lagging.

The Healthcare sector average profit margin is about 13.89%. Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 is at -213.82%, which is lower that average. That is roughly 1639.0% below the sector mean. Use the comparison chart on this page to see how CYCCP stacks up against individual peers as well.

That compares with 8726.37% in the prior-year period — down 102.5% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -213.82%) with ownership activity and broader fundamentals.